CAS: 61-54-1; Tryptamine

相似化合物

343-94-2 319-76-6 879-37-8

上下游产品

CAS号31731-23-4 3-(2-硝基乙基)吲哚 | CAS号103549-24-2 (2-(1H-吲哚-3-基)乙... | CAS号771-51-7 吲哚-3-乙腈 | CAS号1042701-07-4 tert-butyl 4-(2... | CAS号86658-78-8 (2-INDOL-3-YLET... | CAS号73-22-3 L-色氨酸 | CAS号5548-10-7 alpha-氧代-1H-吲哚-3-乙酰胺 | CAS号74321-36-1 (3-Indolyl)acet... | CAS号120-72-9 吲哚 | CAS号112037-79-3 1-(三氟甲基)-9h-吡啶并... | CAS号105891-76-7 5,5-diethyl-6-[... | CAS号111217-41-5 2,2,2-trifluoro... | CAS号50-67-9 5-羟基色胺 | CAS号61-50-7 N,N-二甲基色胺 | CAS号608-07-1 5-甲氧基色胺 | CAS号4307-98-6 2-(1-苄基-1H-吲哚-3... | CAS号3790-45-2 1-苯基-2,3,4,9-四氢... | CAS号16765-79-0 1-苯基-Β-咔啉

L-色氨酸置于rgntdc Enzyme体系中,化学反应生成 色胺
参考文献:基于荧光的卤代色氨酸工程酶筛选
标题:基于荧光的卤代色氨酸工程酶筛选
摘要:定向进化通常受到精确筛选方法的通量的限制.在这里,我们展示了利用单一转录因子(tf)系统的可行性,该系统可以通过两种方式重构(既作为激活子又作为抑制子).具体来说,我们展示了先前进化的 5-卤-或 6-卤-色氨酸特异性 Tf 生物传感器的使用,适用于体内检测卤代色氨酸分子.随后,我们验证了生物传感器在两种卤化酶特异性卤代色氨酸积累筛选中的实用性.首先,我们从卤化酶混合池中以 100% 的效率分离出 5-色氨酸卤化酶 Xshal.此后,我们反应生成了 6-色氨酸卤化酶,Th-Hal 催化残基的靶向文库,并以 100% 的效率分离出功能性卤化酶.最后,我们重构了 Tf 电路以响应卤化色氨酸的消耗,并构建了高通量生物传感器引导的进化方案原型,以筛选能够混杂转化卤化色氨酸的下游酶变体.总而言之,这项工作朝着卤化酶和卤代色氨酸转化酶的快速和更高通量筛选迈出了重要一步,以进一步加强卤化化学品高水平生物生产的努力.
DOI:10.1021/acssynbio.3C00616

专利信息

专利号:US-9446995-B2
优先权日:2012-05-21
标 题:Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
发明人：CHONG HYUN-SOON
权利人:CHONG HYUN-SOON; ILLINOIS INST OF TECH
摘要:Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

专利号:US-10189803-B2
优先权日:2008-02-22
标题 :Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions
发明人：CHONG HYUN-SOON
权利人:CHONG HYUN SOON; ILLINOIS INSTITUTE OF TECH
摘要:Stereoselective and regioselective synthesis of compounds via nucleophilic ring opening reactions of aziridinium ions for use in stereoselective and regioselective synthesis of therapeutic and diagnostic compounds.

专利号:US-11161827-B2
优先权日:2019-04-05
标 题 :Catalytic systems for stereoselective synthesis of chiral amines by enantiodivergent radical C—H amination
发明人：Zhang xiao-xiang; Lang kai
权利人:TRUSTEES BOSTON COLLEGE; THE TRUSTEES OF BOSTON COLLEGE
摘要:In one aspect, the disclosure relates to a mode of asymmetric induction in radical processes based on sequential combination of enantiodifferentiative H-atom abstraction and stereoretentive radical substitution. Also disclosed is an asymmetric system for stereoselective synthesis of strained 5-membered cyclic sulfamides via radical 1,5-C—H amination of sulfamoyl azides. The disclosed metalloradical system can control the degree and sense of asymmetric induction in the catalytic radical C—H amination in a systematic manner. The disclosed system is applicable to a broad scope of substrates with different types of C(sp 3 )—H bonds and exhibits reactivity and selectivity, providing access to both enantiomers of useful 5-membered cyclic sulfamides in a highly enantioenriched form. Also disclosed are catalysts useful in these processes. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

专利号:US-8822702-B2
优先权日:2002-12-20
标 题 :Synthesis of amines and intermediates for the synthesis thereof
发明人：BERENS ULRICH; DOSENBACH OLIVER; SPRENGER DANIEL
权利人:BERENS ULRICH; DOSENBACH OLIVER; SPRENGER DANIEL; BASF SE
摘要:The invention relates in a first embodiment to a method for the manufacture of esters of the formula I, n nor especially of amides of the formula II,n n nwherein the symbols have the meanings given in the specification, as well as other intermediates and compounds useful in the synthesis of tryptamines and other substances mentioned in the title. The synthesis methods and intermediates are useful in the synthesis of pharmaceuticals.

专利号:US-2012130699-A1
优先权日:2010-11-22
标 题 :Method of molecular design and synthesis of therapeutic and preventive drugs
发明人：MARTYNOV ARTUR; FARBER BORIS S; FARBER SONYA SOPHYA
权利人:MARTYNOV ARTUR; FARBER BORIS S; FARBER SONYA SOPHYA
摘要:Industrial Application: This invention may be used in human and veterinary medicine for the design (creation and synthesis) of therapeutic and preventive drugs that are effective for the treatment of oncological and viral human and animal illnesses and for the design of new medicines. n Summary of the Invention: A new method of design and synthesis of therapeutic and preventive drugs in which a biopolymer target (protein, DNA, RNA, or a mixture of these) is used, and in the capacity of a ligand, the same biopolymer target is used, which is cut into oligomer fragments (nucleases, synthetic nucleases, and proteases); the fragments are modified through changing their charges to the opposite charge (acylation of anhydrides of dicarbonate acids or alkylation with halogen-carbonic acids). Also in the capacity of a ligand, the same biopolymer target is used, which is modified by partially changing the molecules' charges to the opposite with the creation of supramolecular biopolymer assemblies. We used supramolecule assemblies made from oligomers that were products of the hydrolysis of biopolymers, but with a change of the charge of the molecules to the opposite charge, as well as the partial change of the charges of the target biopolymers. n Technical Result: A method of molecular design and synthesis of new, unique therapeutic and preventive drugs based on self-organizing systems. The application of the method will allow a significant cut to expenditures on the design and synthesis of new drugs, expand the activity spectra of existing protein gene-engineered drugs, and create new classes of dynamic therapeutic and preventive drugs that self-adapt to the organism and target.

专利号:US-5220016-A
优先权日:1991-07-29
标 题:Synthesis of navelbine analogs
发明人：MAGNUS PHILIP D; THURSTON LEE S
权利人:UNIV TEXAS
摘要:The invention is a de novo synthesis of the norcatharanthine moiety of navelbine. The synthesis includes condensing a Grignard reagent prepared from an amine-protected R(+)-piperidinyl methanol with an N-protected 2-methoxyoxalyl indole. The indole N-protecting group is removed to provide a 2-methoxyindole hydroxy ester which is coupled to vindoline. After removal of the amineprotecting group from the piperidinyl group, ring closure to the indole moiety provides dihydrodesethyl navelbine. Other derivatives and analogs of navelbine with potential clinical applications in cancer chemotherapy may be readily synthesized. The synthesis opens a route to a wide variety of navelbine modifications, including modifications at or near the tryptamine bridge.